Novartis licenses vaccine candidates from U.S. group

ZURICH (Reuters) - Novartis AG will license a program of vaccines from U.S. group AlphaVax against cytomegalovirus (CMV) infections, which can cause disability in newborn babies, the Swiss drugmaker said on Monday.

The deal includes vaccines to prevent Helicobacter pylori infections, a major cause of gastritis that can lead to gastric cancer, and another potential immunization against neonatal sepsis and meningitis.

Novartis will pay AlphaVax $20 million upfront for the investigational CMV program and also has rights of first negotiation on a preclinical respiratory syncytial virus (RSV) program.

There are no approved vaccines to prevent CMV infections and the lead vaccine candidate in the deal is expected to enter mid-stage clinical trials in 2009.

The Swiss company also has an option to make an equity investment at the end of mid-stage trials for 4 million shares. AlphaVax will be eligible for milestones and royalties.

CMV infects about 86,000 newborns in the U.S. and European Union each year, causing 700 deaths and 17,500 cases of severe disability, Novartis said.

(Reporting by Sam Cage)


Related Posts:

ZURICH (Reuters) - Novartis AG’s cancer drug Tasigna was effective and helped achieve rapid responses as an initial therapy in newly diagnosed patients with a life threatening form of leukemia, the company said. Data from two mid-stage clinical trials presented at an American Society of Hematology meeting showed there was rapid elimination of cancer cells in

Full Post: Novartis leukemia drugs show promise

WASHINGTON (Reuters) - More than 54 million U.S. residents, or about 19 percent of the population, have some sort of disability, the U.S. Census Bureau reported on Thursday. The numbers, based on 2005 data, are up slightly from the 2002 survey when 51.2 million people or 18 percent reported a disability, the census found. About 46 percent

Full Post: More than 54 million disabled in U.S., census says

By Katie Reid ZURICH (Reuters) - Swiss voters on Sunday backed a scheme allowing heroin addicts to obtain the drug under prescription, angering conservatives who believe crime will rise as result. Some 68 percent voted in favor of the prescription program that was already approved by parliament, making permanent an experiment that has been in place since

Full Post: Swiss back heroin prescription for addicts

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - An experimental malaria vaccine is the most promising yet, protecting up to 65 percent of infants from infection in two studies in Africa, researchers reported on Monday. Separate tests in Kenya and Tanzania showed GlaxoSmithKline’s vaccine called RTS,S could protect babies and toddlers from infection with malaria

Full Post: Glaxo malaria vaccine protects babies, children

ZURICH (Reuters) - Novartis AG’s Tekturna reduced blood pressure in patients aged 65 and over by significantly more than the older drug ramipril, the Swiss drugmaker said on Tuesday. Data showed that Tekturna — known as Rasilez in Europe — gave an additional reduction in systolic blood pressure of 2.3 millimeters of mercury (mmHG) compared with

Full Post: Tekturna works better in older patients: Novartis

Site Navigation

Most Read